The Europe Large Molecule Bioanalytical Testing Services Market should witness market growth of 9.4% CAGR during the forecast period (2022-2028).
By using specific laboratory investigations, validation entails proving that the method's performance characteristics are reliable and appropriate for the intended analytical applications. The criteria used it to validate the procedure are closely correlated to the acceptability of analytical findings.
It is widely recognized and known that the area of bioanalysis has grown to become an essential instrument in the process of finding and developing new drugs. Numerous assays, including those for significant metabolites, have been constantly created for NCEs over the past few decades to assist various phases of discovery and development. Additionally, a variety of analytical techniques are accessible for both generic and prescription medications.
Chronic diseases are the major cause of mortality and morbidity in Europe region, and research predicts that complicated conditions like diabetes &depression will impose an even higher burden in the future. Chronic disease isthe leading cause of morbidity and mortality in Europe. A number of years ago, chronic diseases were thought of as an issue faced mostly by the wealthy and the older people. Today, people are aware that those of lower socioeconomic status, along with those of younger and middle-aged ages, are more likely to suffer from chronic diseases in countries with high incomes. The consequences for businesses are also very significant when such diseases occur.
The Germany market dominated the Europe Large Molecule Bioanalytical Testing Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $166.5 million by 2028. The UK market is exhibiting a CAGR of 8.5% during (2022-2028). Additionally, The France market would experience a CAGR of 10.2% during (2022-2028).
Based on End-user, the market is segmented into SMEs and Large Firms. Based on Test Type, the market is segmented into Bioavailability, ADME, PD, Bioequivalence, and Others. Based on Type, the market is segmented into ADA, Pharmacokinetics, and Others. Based on Phase, the market is segmented into Clinical and Pre-clinical (With Antibody and Without Antibody (ELISA Based Assay)). Based on Therapeutic Areas, the market is segmented into Oncology, Neurology, Infectious Diseases, Cardiology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc.
By using specific laboratory investigations, validation entails proving that the method's performance characteristics are reliable and appropriate for the intended analytical applications. The criteria used it to validate the procedure are closely correlated to the acceptability of analytical findings.
It is widely recognized and known that the area of bioanalysis has grown to become an essential instrument in the process of finding and developing new drugs. Numerous assays, including those for significant metabolites, have been constantly created for NCEs over the past few decades to assist various phases of discovery and development. Additionally, a variety of analytical techniques are accessible for both generic and prescription medications.
Chronic diseases are the major cause of mortality and morbidity in Europe region, and research predicts that complicated conditions like diabetes &depression will impose an even higher burden in the future. Chronic disease isthe leading cause of morbidity and mortality in Europe. A number of years ago, chronic diseases were thought of as an issue faced mostly by the wealthy and the older people. Today, people are aware that those of lower socioeconomic status, along with those of younger and middle-aged ages, are more likely to suffer from chronic diseases in countries with high incomes. The consequences for businesses are also very significant when such diseases occur.
The Germany market dominated the Europe Large Molecule Bioanalytical Testing Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $166.5 million by 2028. The UK market is exhibiting a CAGR of 8.5% during (2022-2028). Additionally, The France market would experience a CAGR of 10.2% during (2022-2028).
Based on End-user, the market is segmented into SMEs and Large Firms. Based on Test Type, the market is segmented into Bioavailability, ADME, PD, Bioequivalence, and Others. Based on Type, the market is segmented into ADA, Pharmacokinetics, and Others. Based on Phase, the market is segmented into Clinical and Pre-clinical (With Antibody and Without Antibody (ELISA Based Assay)). Based on Therapeutic Areas, the market is segmented into Oncology, Neurology, Infectious Diseases, Cardiology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc.
Scope of the Study
By End-user
- SMEs
- Large Firms
By Test Type
- Bioavailability
- ADME
- PD
- Bioequivalence
- Others
By Type
- ADA
- Pharmacokinetics
- Others
By Phase
- Clinical
- Pre-clinical
- With Antibody
- Without Antibody (ELISA Based Assay)
By Therapeutic Areas
- Oncology
- Neurology
- Infectious Diseases
- Cardiology
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Laboratory Corporation Of America Holdings
- IQVIA Holdings, Inc.
- Syneos Health, Inc.
- SGS S.A.
- Intertek Group PLC
- Pace Analytical Services, LLC
- ICON Plc
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Large Molecule Bioanalytical Testing Services Market by End-user
Chapter 5. Europe Large Molecule Bioanalytical Testing Services Market by Test Type
Chapter 6. Europe Large Molecule Bioanalytical Testing Services Market by Type
Chapter 7. Europe Large Molecule Bioanalytical Testing Services Market by Phase
Chapter 8. Europe Large Molecule Bioanalytical Testing Services Market by Therapeutic Areas
Chapter 9. Europe Large Molecule Bioanalytical Testing Services Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Laboratory Corporation Of America Holdings
- IQVIA Holdings, Inc.
- Syneos Health, Inc.
- SGS S.A.
- Intertek Group PLC
- Pace Analytical Services, LLC
- ICON Plc
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
